Therapeutic potential of natural compounds for treatment of chronic obstructive pulmonary disease: Current status and future perspective

被引:1
|
作者
Sahu, Sanjeev Kumar [1 ]
Rain, Musarraf [1 ]
Vyas, Manish [1 ]
机构
[1] Lovely Profess Univ, Sch Pharmaceut Sci, Jalandhar 144411, Punjab, India
关键词
Chronic obstructive pulmonary disease; Oxidative stress; Reactive oxygen species; Genetic factors; Alpha-1 antitrypsin deficiency; Mitochondria dysfunction; Natural compounds; CIGARETTE-SMOKE; INFLAMMATION; EXTRACT; PATHOGENESIS; EMPHYSEMA;
D O I
10.1016/j.ejmcr.2024.100159
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Chronic obstructive pulmonary disease (COPD) is a lung disease which is the third most common cause of premature death globally. Inhaling dangerous gases, cigarette smoking, and exposure to pollution are the main factors contributing to the development of COPD. These factors may harm lung tissue and create COPD causes. Increased synthesis of inflammatory mediators and proteases because of cigarette smoking exposure to transcriptional factors. Dysfunction of mitochondria essential part to lead and development of several human illnesses, such as chronic obstructive pulmonary disease. Alpha-1 antitrypsin deficiency boosts neutrophil elastase activity, which promotes tissue deterioration and emphysema (particularly in smokers because cigarette smoke also boosts protease activity). In this review, we discussed all these factors and summarized the conventional drug currently present for the treatment of COPD. In addition, we also focused on various natural compounds categorized under the flavonoids, polyphenols, alkaloids, glycosides and marine compounds which were reported for the effective treatment of COPD.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Phenotyping of Chronic Obstructive Pulmonary Disease: Current Approaches and Future Directions
    Luis Lopez-Campos, Jose
    CURRENT RESPIRATORY MEDICINE REVIEWS, 2011, 7 (02) : 138 - 143
  • [22] Current challenges and future scope of nanoparticles in chronic obstructive pulmonary disease
    Pandey, Sarika
    Garg, Rajiv
    Kant, Surya
    Verma, Ajay Kumar
    Gaur, Priyanka
    Agarwal, Megha
    EURASIAN JOURNAL OF PULMONOLOGY, 2021, 23 (01) : 10 - 13
  • [23] THERAPEUTIC POTENTIAL OF ANTIPLATELET AGENTS IN CHRONIC OBSTRUCTIVE PULMONARY-DISEASE
    FERRONI, P
    BASILI, S
    PULCINELLI, FM
    VIERI, M
    SIMEONI, S
    MASSAFRA, S
    CORDOVA, C
    GAZZANIGA, PP
    THROMBOSIS AND HAEMOSTASIS, 1995, 73 (06) : 1448 - 1448
  • [24] Current thoughts regarding treatment of chronic obstructive pulmonary disease
    Celli, BR
    MEDICAL CLINICS OF NORTH AMERICA, 1996, 80 (03) : 589 - +
  • [25] Current utilization of anticholinergics in the chronic obstructive pulmonary disease treatment
    Peña, VS
    Urigoitia, EZ
    REVISTA CLINICA ESPANOLA, 2005, 205 (05): : 223 - 225
  • [26] Epigenetic and current treatment approaches in chronic obstructive pulmonary disease
    Duru, Serap
    TUBERKULOZ VE TORAK-TUBERCULOSIS AND THORAX, 2016, 64 (01): : 47 - 52
  • [27] Current Controversies in the Pharmacological Treatment of Chronic Obstructive Pulmonary Disease
    Singh, Dave
    Roche, Nicolas
    Halpin, David
    Agusti, Alvar
    Wedzicha, Jadwiga A.
    Martinez, Fernando J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 194 (05) : 541 - 549
  • [28] The priorities and concerns for patients with chronic obstructive pulmonary disease in the context of current and potential future service provision
    Alhomoud, Farah
    Robertson, Tricia
    Smith, Felicity
    Taylor, Kevin
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2018, 40 (01) : 216 - 216
  • [29] Current Status of Pulmonary Rehabilitation in Patients With Chronic Obstructive Pulmonary Disease in South Korea
    Joo, H.
    Choi, J.
    Lim, S.
    Rhee, C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [30] Chronic Obstructive Pulmonary Disease 2 The future of chronic obstructive pulmonary disease treatment-difficulties of and barriers to drug development
    Martinez, Fernando J.
    Donohue, James F.
    Rennard, Stephen I.
    LANCET, 2011, 378 (9795): : 1027 - 1037